Martha Stewart's recipe for acquittal begins with selecting the most sympathetic jury. In preparation for a Jan. 20 showdown with federal prosecutors in New York City, her legal team spent last week sifting through hundreds of 35-page juror questionnaires that probed such matters as whether people had ever purchased a Martha Stewart product or heard of the biotech firm ImClone. The fate of the domestic diva, who faces charges stemming from her sale of 3,928 ImClone shares shortly before the stock price plummeted in 2001, hinges on whether the jury sees her as a cover-up artist or as a victim of...
To continue reading:
or
Log-In
